Twist Bioscience Stock Price, News & Analysis

Twist Bioscience (NASDAQ: TWST) announced early access to its enhanced Whole Genome Sequencing (eWGS) solution for non-human genomics at the AGBT 2023 meeting in Hollywood, Florida. This innovative solution allows researchers to obtain simultaneous low-pass whole genome data with deep coverage of specific regions, enhancing cost-effectiveness and high throughput. The eWGS workflow uses a modified 96-plex library preparation kit, facilitating the sequencing of 96 samples in a single tube, aimed at improving resolution and flexibility in agricultural genomics. Additionally, Twist will present three posters on next-generation sequencing and reference standards during the conference.

Twist Bioscience Corporation (NASDAQ: TWST) reported a strong start to fiscal 2023, with revenue of $54.2 million in the first quarter, reflecting a 29% increase from $42.0 million in the same quarter last year. Total orders rose to $64.7 million, a 30% increase year-over-year. Despite a net loss of $41.8 million, improvements were noted in expenses: Selling, General and Administrative costs dropped from $51.1 million to $42.3 million. The company shipped products to 2,060 customers and launched key partnerships in biopharma and DNA storage, showcasing robust growth and innovation in its core business areas.

Twist Bioscience Corporation (NASDAQ: TWST) announced the shipment of initial products from its new manufacturing facility in Wilsonville, Oregon, known as the Factory of the Future. This 110,000 square-foot facility is expected to double the company's manufacturing capacity, supporting substantial growth in production and revenue. CEO Emily M. Leproust expects the enhanced capacity will facilitate new product introductions, including 'fast genes' that promise quicker manufacturing turnaround times. Currently, the company offers turnaround times of 10 business days for clonal genes and 5 business days for gene fragments and oligo pools.

Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2023 Q1 financial results on February 3, 2023, before market opening. A conference call and live audio webcast will follow at 8:00 a.m. ET, aimed at discussing the results and providing business updates. The press release with details will be available on Twist's Investor Relations page.

Twist is a leader in synthetic biology and genomics, utilizing a cutting-edge DNA synthesis platform built on silicon technology, serving various sectors including healthcare and agriculture.

Twist Bioscience (TWST) and Centogene (CNTG) have launched three next-generation sequencing target enrichment panels aimed at advancing research and diagnostics for rare diseases and hereditary cancers. These panels enhance the precision of genetic sequencing and are based on data from Centogene's Biodatabank, which includes nearly 700,000 patients. The products include the Twist Alliance CNTG Exome Panel, CNTG Rare Disease Panel, and CNTG Hereditary Oncology Panel. This collaboration is expected to improve diagnostic capabilities worldwide, facilitating earlier disease detection and treatment development.

Twist Bioscience (NASDAQ: TWST) has announced a research collaboration with Astellas Pharma Inc to discover antibodies targeting diseases with high unmet medical needs. This partnership, following a successful initial collaboration, highlights Twist's antibody discovery capabilities through its Library of Libraries. Under the agreement, Twist will receive an upfront payment, project-specific research fees, and earn up to $11 million USD per product for clinical milestones, along with royalties on product sales. Astellas will handle product development and commercialization.

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 41st Annual J.P. Morgan Health Care Conference on January 9th at 5:15 p.m. PST. The live presentation will be webcast and accessible via the company's investor relations page. A replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA production using its proprietary silicon platform to create products for various sectors including healthcare and agriculture.

Twist Bioscience Corporation (NASDAQ: TWST) will host investors at its Factory of the Future on November 29, 2022. During this event, CEO Emily M. Leproust and CFO Jim Thorburn will engage in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30 at 4:20 p.m. ET. The presentation will be webcast live, with an archive available for 30 days. Twist Bioscience, a leader in synthetic biology, provides high-quality synthetic DNA using a proprietary silicon platform, enhancing applications across multiple industries.

Twist Bioscience reported record revenue of $203.6 million for Fiscal 2022, marking a 54% increase from the previous year. Orders rose to $226 million, up 42% year-over-year. The company forecasts revenue between $261 million and $269 million for Fiscal 2023 and anticipates $350 million in Fiscal 2024. Despite growth, net loss for Fiscal 2022 widened to $217.9 million, or $4.04 per share. The company aims to enhance its position in next-generation sequencing (NGS) and introduce new products in 2023, including a DNA data storage solution.